Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
:NPCE
NPCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.45 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)170.99K
Market Cap
$361.25M
Enterprise Value$375.47M
Total Cash (Recent Filing)$62.14M
Total Debt (Recent Filing)$71.52M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 11, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding33,081,497
10 Day Avg. Volume139,976
30 Day Avg. Volume170,988
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue4.24
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda-23.14
Forecast
1Y Price Target
$16.67Price Target Upside52.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Guidance And ExpectationsRevenue guidance for NPCE has been raised more than the beat, indicating confidence in the company's future performance.
Regulatory ProgressFDA discussions for IGE are progressing well, with an expected accelerated review timeline following PMA supplement submission.
Revenue GrowthNPCE reported 2Q25 sales of $23.5 million, which is 2% higher than consensus and shows a year-over-year growth of 22%.
Bears Say
Clinical Trial ResultsThe study did not reach statistical significance for the primary effectiveness endpoint, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $5.45 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $361.25M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 36 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,081,497 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went up 2.081%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (52.66% Upside)
$16.67 (52.66% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 187.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.12%
12-Months-Change
Fundamentals
Return on Equity
-176.94%
Trailing 12-Months
Asset Growth
12.42%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with record revenue and improved gross margins, alongside successful debt refinancing and positive clinical trial data. However, challenges included increased operating expenses, a higher net loss, and the NAUTILUS trial not meeting its primary effectiveness endpoint.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$16.67
▲(52.66% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
27.52% Insiders
6.67% Mutual Funds
0.52% Other Institutional Investors
49.60% Public Companies and
Individual Investors